India Globalization Capital

Update in progress

IGC (NYSE American)

IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on neuropsychiatric and neurodegenerative disorders, with emphasis on Alzheimer's disease in the United States and Colombia. Its lead drug, IGC-AD1, is in Phase II for agitation in dementia due to Alzheimer's. Preclinical candidates include TGR-63 and IGC-M3. The company is also developing MINT-AD, an AI assistant for clinicians. Formerly India Globalization Capital, renamed in 2023; founded 2005; based in Potomac, Maryland.